¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"active iodine"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active immunization
    ´Éµ¿¸é¿ªÈ­
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
  • active marrow
    Ȱ¼º°ñ¼ö
  • active material
    Ȱ¼º¹°Áú, Ȱ¼ºÀç
  • active movement
    ´Éµ¿¿îµ¿
  • active negativism
    Àû±Ø°ÅºÎÁõ
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • active phase
    Ȱ¼º±â
  • active placebo
    Ȱ¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active material
    Ȱ¼º¹°Áú
  • active movement
    ´Éµ¿¿îµ¿
  • active negativism
    Àû±Ø°ÅºÎÁõ
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • active placebo
    ¾ç¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿°¡¸², ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
  • active tuberculosis
    Ȱµ¿°áÇÙ
  • active gradient shielding
    ´Éµ¿±â¿ï±âÂ÷Æó, ´Éµ¿°æ»çÂ÷Æó
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active gradient shielding
    ´Éµ¿ °æ»ç Â÷Æó
  • active hydrogen
    Ȱ¼º¼ö¼Ò(¡­â©áÈ).
  • active imagination
    Àû±ØÀû »ó»ó
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹).
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active incorporative mode
    Àû±ØÀû ÇÔÀÔ ¾ç½Ä
  • active marrow
    Àû°ñ¼ö.
  • active material
    Ȱ¼º¹°Áú(üÀàõÚªòõ).
  • active movement
    ´Éµ¿¿îµ¿(ÒöÔÑê¡ÔÑ)
  • active negativism
    Àû±Ø¼º °ÅÀýÁõ.
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • active shielding
    ´Éµ¿ Â÷Æó
  • active shimming
    ´Éµ¿ º¸Á¤
  • active site
    Ȱ¼ºÀÚ¸®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • radioactive iodine
    ¹æ»ç¼º ¿ä¿Àµå.
  • radioactive iodine labeled human serum albumin
    ¹æ»ç¼º ¿ä¿ÀµåÇ¥ÁöÀÎÇ÷û(¡­ øöãÛìÑúìôè)¾ËºÎ¹Î.
  • serum protein bound iodine
    Ç÷û´Ü¹é°áÇÕ ¿äµå.
  • thyroid radioactive iodine uptake
  • tincture of iodine
    ¿ä¿ÀµåÆÃÅ©.
  • active
    Ȱµ¿¼º(üÀÔÑàõ), ´Éµ¿¼º(ÒöÔÑàõ).
  • active hyperemia
    ´Éµ¿Àû Ç÷·ùÁõ°¡(ÒöÔÑîÜúì×µñòÊ¥)
  • active apperception
    ÀÚµ¿(Àû)Åë°¢(ÀÛ¿ë)(í»ÔÑîÜ÷ÖÊÆíÂéÄ).
  • active carbon
    Ȱ¼ºÅº(üÀàõ÷©).
  • active earth
    Ȱ¼ºÅä(Ì·ËÛ̬).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active force generation test
    ±Ù·Â°Ë»ç
  • active glycine
    Ȱ¼º(üÀàõ)±Û¸®½Å.
  • active gradient shielding
    ´Éµ¿ °æ»ç Â÷Æó
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active carbohydrate
    Ȱ¼º´çÁú (üÀàõÓØòõ)
  • active carbon
    Ȱ¼ºÅº (üÀàõ÷©)
  • active carbon dioxide
    Ȱ¼ºÀÌ»êȭź¼Ò (üÀàõì£ß«ûù÷©áÈ)
  • active center
    Ȱ¼ºÁß½É(üÀàõñéãý)
  • active concentration
    Ȱ¼º³óµµ(üÀàõÒØÓø)
  • active form
    Ȱ¼ºÇü(üÀàõû¡)
  • active formaldehyde
    Ȱ¼º(üÀàõ)Æ÷¸§¾Ëµ¥ÇÏÀ̵å
  • active formate
    Ȱ¼º(üÀàõ)Æ÷¸§»ê(ß«)
  • active formimino
    Ȱ¼º(üÀàõ) Æ÷¸§À̹̳ë
  • active fructose
    Ȱ¼º(üÀàõ)ÇÁ¶ôÅäÁî
  • active glycolaldehyde
    Ȱ¼º(üÀàõ)±Û¸®Äݾ˵¥ÇÏÀ̵å
  • active hydroxyethyl
    Ȱ¼º(üÀàõ)ÇÏÀ̵å·Ï½Ã¿¡Æ¿
  • active hydroxymethyl
    Ȱ¼º(üÀàõ)ÇÏÀ̵å·Ï½Ã¸ÞÆ¿
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹)
  • active mediated transport
    ´Éµ¿¸Å°³¼ö¼Û (ÒöÔÑØÚË¿âÃáê)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PBI   1) Penile Brachial Index
  2) Protein-Bound Iodine; ´Ü¹é °áÇÕ ¿ä¿Àµå
AIIT amiodarone-iodine-induced thyrotoxicosis
AIU absolute iodine uptake; antigen-inducing unit
BEI back-scattered electron imaging; biological exposure indexes; butanol-extractable iodine
BII beat inclusion index; Billroth II [operation]; butanol-insoluble iodine
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ID Iodine deficiency
[123I] MIBG Iodine-123 meta-iodobenzylguanidine
MIBG Iodine-123-Metaiodobenzylguanidine
I-131 Iodine-131
131I-MIBG Iodine-131 metaiodobenzylguanidine
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • active immunity
    ´Éµ¿ ¸é¿ª
    Ç׿ø Àڱؿ¡ ¹ÝÀÀÇÏ¿© »ý»êµÈ Ç×ü³ª ¸é¿ª ¸²ÇÁ°è ¼¼Æ÷ÀÇ Á¸Àç·Î ÀÎÇÑ È¹µæ¸é¿ª. »ç¶÷¿¡ ´ëÇØ¼­ ¹é½ÅÀ̳ª µ¶¼ºÀ¸·Î ¸é¿ªÇÏ´Â °ÍÀ¸·Î ÀÚ½ÅÀÇ ¸öÀ¸·Î ¸é¿ªÀ» ¸¸µé¾î³»¹Ç·Î È¿°ú´Â ¿À·¡ Áö¼ÓµÈ´Ù.
  • active mandibular opening
    ´Éµ¿ ÇÏ¾Ç °³±¸
    ±æÇ×±Ù
  • active material
    Ȱ¼º ¹°Áú
    È­ÇÐ ¹ÝÀÀ¿¡ À־ Ã˸ÅÀÇ ¹ÝÀÀ ÃËÁø ´É·ÂÀ» Ȱ¼ºÈ­ ½ÃŰ´Â ¹°Áú.
  • active myofascial trigger point
    Ȱµ¿¼º ±Ù¸· ¹ßÅëÁ¡
    ÃËÁøÀ» ÅëÇØ ÀÚ±ØÀ» ÁÖÁö ¾Ê´õ¶óµµ ±¹¼ÒÀûÀ̰ųª ÀüÀÌµÈ ÅëÁõÀ̳ª Áõ»óÀ» ³ªÅ¸³»´Â ±Ù¸· ¹ßÅëÁ¡.
  • active principle
    À¯È¿¼ººÐ
    ¾à¹°ÀÇ È¿°ú¸¦ ºÎ¿©ÇÏ´Â ¾à¹° ÁßÀÇ ¼ººÐ
  • active relaxation therapy
    ´Éµ¿ ÀÌ¿Ï ¿ä¹ý
  • active sensitization
    ´Éµ¿ °¨ÀÛ, ´Éµ¿Àû °¨ÀÛ
    »ýü¿¡ Ç׿øÀ» ÁÖ»çÇÑ °á°ú ³ªÅ¸³ª´Â ¿¹¹Î¼º.
  • active shimming
    ´Éµ¿ º¸Á¤
  • active state
    Ȱµ¿ »óÅÂ
    ±ÙÀ°ÀÌ ¼öÃàÇÒ ¶§, ¼öÃà¿ä¼Ò ÀÚü¿¡ ÀϾ°í ÀÖ´Â ¿ªÇÐÀû »óÅÂÀÌ´Ù. ±ÙÀ° ÀÚü¿¡ ź¼º¿ä¼Ò°¡ Á¸ÀçÇϹǷΠ´Ü¼øÇÑ ¼öÃà°î¼±ÀÇ ±â·ÏÀ¸·Î Ȱµ¿»óȲÀ» ¾Ë ¼ö ¾ø´Ù. ¼öÃà¿ä¼Ò´Â ±ÙÀ°ÀÌ ÀڱصǸé Áï½Ã Ȱµ¿»óŰ¡ µÇ°í, Á¦2, Á¦3ÀÇ ÀÚ±ØÀÌ °¡ÇØÁ®µµ ÀÌ È°µ¿»óÅ´ °­È­µÇÁö ¾Ê°í ´Ü¼øÈ÷ Áö¼Ó½Ã°£ÀÌ ¿¬ÀåµÉ »ÓÀÌ´Ù.
  • active transport
    ´Éµ¿ À̵¿
    È®»ê¿¡ ÀÇÇØ¼­°¡ ¾Æ´Ï¶ó ¿î¹Ýü¿¡ ÀÇÇØ ¿¡³ÊÁö¸¦ ¼ÒºñÇØ °¡¸ç ³óµµ¿¡ ¿ªÇàÇØ¼­ ¹°ÁúÀÌ À̵¿µÇ´Â Çö»ó.
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ, Ȱµ¿¼º °áÇÙÁõ
    ȯÀÚ¿¡¼­ ±ÕÀÌ °ËÃâµÇ´Â »óÅ¿¡ ÀÖ´Â °áÇÙ.
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • coagualtion-active substance
    ÀÀ°í Ȱ¼º ¹°Áú
  • full active opening
    ´Éµ¿ °³±¸·®
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
iodine-123 <radiobiology> A radioisotope of iodine with a 159 keV gamma emission and a physical half-life of 13.2 hr, frequently used for studies of thyroid disease and of renal function.
(05 Mar 2000)
iodine-125 <radiobiology> Radioactive iodine isotope that decays by K-capture (internal conversion) with a half-life of 59.4 days; used as a tracer in thyroid studies and as a label in immunoassay and in imaging.
(05 Mar 2000)
iodine-127 <radiobiology> Stable, nonradioactive iodine, the most abundant iodide isotope found in nature; dietary deficiency causes simple goiter; used to block thyroid uptake of radioactive iodine released from nuclear accidents.
(05 Mar 2000)
iodine-131 <radiobiology> A radioactive iodine isotope, 364 keV peak beta and gamma emitter with a half-life of 8 days.
It is used as a tracer in thyroid studies, as therapy in hyperthyroidism, thyroid cancer, and heart disease, and as a label in immunoassay and imaging.
(22 Sep 2002)
iodine-132 <radiobiology> A beta-and gamma-emitting radioisotope of iodine with a physical half-life of 2.28 hr, usually obtained from a tellurium-132 radionuclide generator; its clinical use has been supplanted by 131I and 123I.
(05 Mar 2000)
iodine compounds Inorganic compounds that contain iodine as an integral part of the molecule.
(12 Dec 1998)
iodine cysts An obsolete term used to indicate the cyst's of Iodamoeba butschlii, characterised by a large iodine-positive glycogen vacuole.
(05 Mar 2000)
iodine deficiency Iodine is a natural requirement of our diets. Iodine deficiency can lead to inadequate production of thyroid hormone from the thyroid gland (hypothyroidism). For example, in some parts of zaire, ecuador, india, and chile, remote, mountainous areas, such as in the alps (in the past), andes and the himalayas have a particular predisposition to severe iodine deficiency, goiter, and hypothyroidism. Since the addition of iodine to table salt, iodine deficiency is rarely seen in the united states.
(12 Dec 1998)
iodine excess Just as too little iodine can cause thyroid disease, so may prolonged intake of too much iodine also lead to the development of goiter (swelling of the thyroid gland) and hypothyroidism (abnormally low thyroid activity). Certain foods and medications contain large amounts of iodine. Examples include seaweed; iodine-rich expectorants (such as sski and lugol's solution) used in the treatment of cough, asthma, chronic pulmonary disease; and amiodarone (cardorone), an iodine-rich medication used in the control of abnormal heart rhythms (cardiac arrhythmias).
(12 Dec 1998)
iodine-fast Denoting hyperthyroidism unresponsive to iodine therapy, which develops frequently in most cases so treated.
(05 Mar 2000)
iodine-induced hyperthyroidism <endocrinology> Induction of thyrotoxicosis in a previously euthyroid individual as a result of exposure to large quantities of iodine.
It occurs most often in areas of endemic iodine-deficient goiter and in patients with multinodular goiter. It can also can develop following use of iodine-containing agents for diagnostic studies.
Synonym: iodine-induced hyperthyroidism.
(05 Mar 2000)
iodine isotopes Stable iodine atoms that have the same atomic number as the element iodine, but differ in atomic weight. I-127 is the only naturally occurring stable iodine isotope.
(12 Dec 1998)
iodine number An indication of the quantity of unsaturated fatty acids present in a fat; it represents the number of grams of iodine absorbed by each 100 g of fat.
See: hydrogen number.
Synonym: iodine value.
(05 Mar 2000)
iodine radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
(12 Dec 1998)
iodine reaction of epinephrine A reaction resulting from the oxidation of the hormone, a faint pink colour appearing upon the addition of iodine.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á